Halozyme Therapeutics, Inc. (HALO)

NMS – Real vaqt narxi. Valyuta: USD

70.93

+4.52 (6.81%)

Yopilishda: May 12, 2026, 4:00 PM EDT

71.35

+0.42 (0.59%)

Bozor oldidan: May 13, 2026, 8:47 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Halozyme Therapeutics, Inc. (HALO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Videolar

No Data

Press-relizlar

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Search stocks

Halozyme Therapeutics, Inc. (HALO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Videolar

No Data

Press-relizlar

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Halozyme Appoints Darren Snellgrove as Chief Financial Officer